CIK 0001133416 · Non-accelerated filer<br>Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 043562325
- Phone
- 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-18 | LEWIS JOEL President and CEO | Sale 10b5-1 | −6,783 | $6.15 | $42K | 832,592 |
| 2025-11-18 | LEWIS JOEL President and CEO | Option exercise · Stock option (right to buy) 10b5-1 | −6,783 | 0 | ||
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +28,100 | $1.98 | $56K | 35,714 |
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −28,100 | $6.22 | $175K | 7,614 |
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +18,210 | $1.11 | $20K | 25,824 |
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −18,210 | $6.22 | $113K | 7,614 |
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −28,120 | 0 | ||
| 2025-11-18 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Common stock (right to buy) 10b5-1 | −18,190 | 0 | ||
| 2025-11-17 | LEWIS JOEL President and CEO | Option exercise 10b5-1 | +15,680 | $2.39 | $37K | 848,272 |
| 2025-11-17 | LEWIS JOEL President and CEO | Sale 10b5-1 | −15,680 | $6.04 | $95K | 832,592 |
| 2025-11-17 | LEWIS JOEL President and CEO | Option exercise · Stock option (right to buy) 10b5-1 | −15,680 | 6,783 | ||
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +9,586 | $1.98 | $19K | 17,200 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −9,586 | $6.03 | $58K | 7,614 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +19,701 | $1.11 | $22K | 27,315 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −19,701 | $6.03 | $119K | 7,614 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +2,323 | $1.23 | $3K | 9,937 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −2,323 | $6.03 | $14K | 7,614 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −9,586 | 28,120 | ||
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −19,701 | 18,190 | ||
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −2,323 | 48,750 |
Page 7 of 15 · 291 trades